Janssen picks up Roche rejects from Evotec
This article was originally published in Scrip
Executive Summary
Evotec has exclusively licensed to Janssen Pharmaceuticals a portfolio of small-molecule selective NMDA antagonists for development against depression. The portfolio had been licensed to Roche, which terminated the agreement in 2011.